Clinical trial
Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine…
NCT00288925 · Zeria Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00288925 |
|---|---|
| Title | Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment |
| Official title | Phase Ib/IIa, to Evaluate the Safety and Pharmacokinetics of Z-360 in Subjects With Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment |
| Lead sponsor | Zeria Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Z-360 |
| Enrollment | 30 |
| Start date | Sep 1, 2005 |
| Primary completion | Dec 1, 2007 |
| First posted | Feb 8, 2006 |
| Last update posted | Jun 1, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: